Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsRodrigo Fonseca, Joseph Mıkhael, A. Keith Stewart et al.|Blood Cancer Journal|2023Cited by 25
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsRodrigo Fonseca, Rafaël Fonseca, Mariano Arribas et al.|Research Square|2022Cited by 3
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo ClinicYael Kusne, Rafaël Fonseca, Rodrigo Fonseca et al.|Blood|2022Cited by 1
Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsRodrigo Fonseca, Mariano Arribas, Julia E. Wiedmeier et al.|Blood Cancer Journal|2023Cited by 1
Electrocardiogram As a Marker of Cardiac Response in Light Chain AmyloidosisRodrigo Fonseca, Julie Rosenthal, Yael Kusne et al.|Blood|2022Cited by 0